Your browser doesn't support javascript.
loading
Cross-sectional study evaluating the impact of SARS-CoV-2 variants on Long COVID outcomes in UK hospital survivors.
Saigal, Anita; Nagoda Niklewicz, Camila; Naidu, Sindhu Bhaarrati; Bintalib, Heba M; Shah, Amar Jitu; Seligmann, George; Hunter, Alan Stewart; Wey, Emmanuel; Abubakar, Ibrahim; Mahungu, Tabitha; Miller, David; Barnett, Joseph; Jain, Neel Gautam; Brill, Simon; Goldring, James; Jarvis, Hannah; Smith, Colette; Ogbonnaya, Chibueze; Hurst, John R; Lipman, Marc C I; Mandal, Swapna.
Affiliation
  • Saigal A; UCL Respiratory, University College London, London, UK rmhaa56@ucl.ac.uk.
  • Nagoda Niklewicz C; Respiratory Medicine, Royal Free London NHS Foundation Trust, London, UK.
  • Naidu SB; Respiratory Medicine, Royal Free London NHS Foundation Trust, London, UK.
  • Bintalib HM; Respiratory Medicine, Royal Free London NHS Foundation Trust, London, UK.
  • Shah AJ; UCL Respiratory, University College London, London, UK.
  • Seligmann G; UCL Respiratory, University College London, London, UK.
  • Hunter AS; Respiratory Medicine, Royal Free London NHS Foundation Trust, London, UK.
  • Wey E; Respiratory Medicine, Royal Free London NHS Foundation Trust, London, UK.
  • Abubakar I; Department of Infectious Diseases, Royal Free London NHS Foundation Trust, London, UK.
  • Mahungu T; Department of Infectious Diseases, Royal Free London NHS Foundation Trust, London, UK.
  • Miller D; Centre for Clinical Microbiology, Division of Infection and Immunity, University College London, London, UK.
  • Barnett J; UCL Respiratory, University College London, London, UK.
  • Jain NG; Faculty of Population Health Sciences, University College London, London, UK.
  • Brill S; Department of Virology, Royal Free London NHS Foundation Trust, London, UK.
  • Goldring J; Open Health Care, London, UK.
  • Jarvis H; Department of Radiology, Royal Free London NHS Foundation Trust, London, UK.
  • Smith C; Department of Radiology, Royal Free London NHS Foundation Trust, London, UK.
  • Ogbonnaya C; Respiratory Medicine, Royal Free London NHS Foundation Trust, London, UK.
  • Hurst JR; Respiratory Medicine, Royal Free London NHS Foundation Trust, London, UK.
  • Lipman MCI; Respiratory Medicine, Royal Free London NHS Foundation Trust, London, UK.
  • Mandal S; Institute of Global Health, University College London, London, UK.
BMJ Open Respir Res ; 10(1)2023 08.
Article in En | MEDLINE | ID: mdl-37536948
ABSTRACT

OBJECTIVES:

COVID-19 studies report on hospital admission outcomes across SARS-CoV-2 waves of infection but knowledge of the impact of SARS-CoV-2 variants on the development of Long COVID in hospital survivors is limited. We sought to investigate Long COVID outcomes, aiming to compare outcomes in adult hospitalised survivors with known variants of concern during our first and second UK COVID-19 waves, prior to widespread vaccination.

DESIGN:

Prospective observational cross-sectional study.

SETTING:

Secondary care tertiary hospital in the UK.

PARTICIPANTS:

This study investigated Long COVID in 673 adults with laboratory-positive SARS-CoV-2 infection or clinically suspected COVID-19, 6 weeks after hospital discharge. We compared adults with wave 1 (wildtype variant, admitted from February to April 2020) and wave 2 patients (confirmed Alpha variant on viral sequencing (B.1.1.7), admitted from December 2020 to February 2021). OUTCOME

MEASURES:

Associations of Long COVID presence (one or more of 14 symptoms) and total number of Long COVID symptoms with SARS-CoV-2 variant were analysed using multiple logistic and Poisson regression, respectively.

RESULTS:

322/400 (wave 1) and 248/273 (wave 2) patients completed follow-up. Predictors of increased total number of Long COVID symptoms included pre-existing lung disease (adjusted count ratio (aCR)=1.26, 95% CI 1.07, 1.48) and more COVID-19 admission symptoms (aCR=1.07, 95% CI 1.02, 1.12). Weaker associations included increased length of inpatient stay (aCR=1.02, 95% CI 1.00, 1.03) and later review after discharge (aCR=1.00, 95% CI 1.00, 1.01). SARS-CoV-2 variant was not associated with Long COVID presence (OR=0.99, 95% CI 0.24, 4.20) or total number of symptoms (aCR=1.09, 95% CI 0.82, 1.44).

CONCLUSIONS:

Patients with chronic lung disease or greater COVID-19 admission symptoms have higher Long COVID risk. SARS-CoV-2 variant was not predictive of Long COVID though in wave 2 we identified fewer admission symptoms, improved clinical trajectory and outcomes. Addressing modifiable factors such as length of stay and timepoint of clinical review following discharge may enable clinicians to move from Long COVID risk stratification towards improving its outcome.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Humans Country/Region as subject: Europa Language: En Journal: BMJ Open Respir Res Year: 2023 Type: Article Affiliation country: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Humans Country/Region as subject: Europa Language: En Journal: BMJ Open Respir Res Year: 2023 Type: Article Affiliation country: United kingdom